Condition
Mesothelioma
Estimated Enrollment: 23
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 1839IL/0094
Study First Received: November 6, 2008
Last Updated: June 5, 2012
Estimated Primary Completion Date: April 2008
Primary Outcome Measures:
To assess the activity of ZD1839 in patients with malignant mesothelioma by estimating the objective response rate (CR and PR) at trial closure|To further characterize the safety profile of ZD1839 at a 250mg daily dose|To estimate PFS (progression free survival)|To estimate overall survival|To estimate duration of response
Sponsors and Collaborators:
AstraZeneca
Website Link: https://ClinicalTrials.gov/show/NCT00787410
